PUBLISHER: Grand View Research | PRODUCT CODE: 1750647
PUBLISHER: Grand View Research | PRODUCT CODE: 1750647
The global DNA-encoded library market size is expected to reach USD 1.60 billion by 2030, growing at a CAGR of 13.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising demand for novel and targeted drug discovery is one of the key factors driving the market growth. These libraries enable high-throughput screening of vast chemical compounds, significantly accelerating the identification of potential drug candidates. Traditional methods for screening chemical compounds can be time-consuming and resource-intensive, but DNA-encoded libraries streamline this process by attaching a unique DNA sequence to each compound, making it possible to rapidly identify and evaluate numerous candidates simultaneously. This efficiency is a major advantage in drug discovery, where speed and accuracy are critical.
Another significant factor propelling the growth of the DNA-encoded library industry is the increasing focus on precision medicine. As the healthcare industry moves toward more personalized treatments, the ability to discover drugs that specifically target individual genetic profiles becomes more valuable. DNA-encoded libraries offer a unique solution by enabling the creation of highly diverse libraries that can be tailored to target specific disease pathways or patient populations. This is particularly beneficial in the fields of oncology and genetic disorders, where personalized therapies have shown great promise in improving treatment outcomes.
The rising prevalence of chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, is also contributing to the market growth. The increasing burden of these diseases worldwide has spurred investments in drug discovery technologies that can lead to faster development of effective treatments. DNA-encoded libraries play a critical role in this by facilitating the discovery of novel small molecules, antibodies, and other biologics that can potentially address unmet medical needs. In particular, the growing interest in antibody-based therapies and immunotherapies has highlighted the importance of efficient drug discovery methods like DNA-encoded libraries.
Technological advancements in genomics and bioinformatics have further fueled the market's growth. As sequencing technologies have become more advanced and cost-effective, the ability to construct large, highly diverse DNA-encoded libraries has improved. The integration of bioinformatics tools has also enhanced the ability to analyze complex data, allowing researchers to optimize the selection of candidates and improve the efficiency of the drug discovery process. These advancements have made DNA-encoded libraries more accessible and effective, driving their adoption across pharmaceutical and biotechnology companies.
In addition, the increasing number of collaborations and partnerships between pharmaceutical companies, academic institutions, and contract research organizations is driving market expansion. These collaborations enable the sharing of resources and expertise, accelerating the development and application of DNA-encoded library technology in drug discovery. The market is also supported by increasing funding from both public and private sectors, as the potential for breakthrough drugs remains high. Together, these factors are creating a conducive environment for the growth and expansion of the DNA-encoded library market.